Advanced Therapeutics最新文献

Issue Information (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570012

引用次数: 0

Antibiotic–Polycationic Peptide Conjugation as an Effective Strategy to Overcome Daptomycin Resistance (Adv. Therap. 5/2025)

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-05-14 DOI: 10.1002/adtp.202570011

Sari Rasheed, Florian Umstätter, Eric Mühlberg, Barbro Beijer, Tobias Hertlein, Karel D. Klika, Christian Kleist, Julia Werner, Cornelius Domhan, Mara Bingel, Anna Müller, Marvin Rausch, Stefan Zimmermann, Knut Ohlsen, Uwe Haberkorn, Marcus Koch, Markus Bischoff, Tanja Schneider, Rolf Müller, Jennifer Herrmann, Walter Mier, Philipp Uhl

引用次数: 0

Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms 合成黏液生物材料与抗菌膜剂协同对抗铜绿假单胞菌生物膜

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-29 DOI: 10.1002/adtp.202400359

Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan

{"title":"Synthetic Mucus Biomaterials Synergize with Antibiofilm Agents to Combat Pseudomonas aeruginosa Biofilms","authors":"Sydney Yang, Allison Boboltz, Alexa Stern, Vaidehi Rathi, Gregg Duncan","doi":"10.1002/adtp.202400359","DOIUrl":"https://doi.org/10.1002/adtp.202400359","url":null,"abstract":"Bacterial biofilms are often highly resistant to antimicrobials causing persistent infections which, when not effectively managed, can significantly worsen clinical outcomes. As such, alternatives to standard antibiotic therapies have been highly sought after to address difficult-to-treat biofilm-associated infections. A biomaterial-based approach using the innate functions of mucins is hypothesized to modulate bacterial surface attachment and virulence can provide a new therapeutic strategy against biofilms. Based on the testing in Pseudomonas aeruginosa biofilms, it is found that synthetic mucus biomaterials can inhibit biofilm formation and significantly reduce the thickness of mature biofilms. In addition, if synthetic mucus biomaterials can work synergistically with DNase and/or α-amylase for enhanced biofilm dispersal is evaluated. Combination treatment with these antibiofilm agents and synthetic mucus biomaterials resulted in up to 2 log reductions in the viability of mature P. aeruginosa biofilms. Overall, this work provides a new bio-inspired, combinatorial approach to address biofilms and antibiotic-resistant bacterial infections.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400359","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanoparticles Combining Host-Directed Therapeutics and Antibiotics to Boost Bacterial Killing and Overall Survival of Zebrafish Embryos Infected with Mycobacterium Marinum (Adv. Therap. 4/2025) 结合宿主导向疗法和抗生素的纳米颗粒提高感染海洋分枝杆菌的斑马鱼胚胎的细菌杀伤和总体存活率（ad . therapp . 4/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570009

Gabriela Schäfer, Dongdong Bi, Federico Fenaroli, Andrew M. Thompson, Anno Saris, Matthias Barz

引用次数: 0

Issue Information (Adv. Therap. 4/2025) 发行信息（ad . therapy . 4/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-18 DOI: 10.1002/adtp.202570010

引用次数: 0

Hydroxyapatite Binding Peptide Lipid Nanoparticles for Biomimetic mRNA Delivery to Bone 羟基磷灰石结合肽脂纳米颗粒用于骨仿生mRNA递送

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-17 DOI: 10.1002/adtp.202400505

Joshua A. Choe, Jena E. Moseman, Jamie M. Jones, Jacobus C. Burger, Ashley M. Weichmann, Douglas G. McNeel, William L. Murphy

引用次数: 0

Insights on Advances in 3D Bioprinting for Peripheral Nerve Regeneration

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-04-03 DOI: 10.1002/adtp.202400506

Nasera Rizwana, Samartha M C, Ashwath Acharya, Goutam Thakur, Manasa Nune, Vipul Agarwal

{"title":"Insights on Advances in 3D Bioprinting for Peripheral Nerve Regeneration","authors":"Nasera Rizwana, Samartha M C, Ashwath Acharya, Goutam Thakur, Manasa Nune, Vipul Agarwal","doi":"10.1002/adtp.202400506","DOIUrl":"https://doi.org/10.1002/adtp.202400506","url":null,"abstract":"Peripheral nerve injury is a common injury that impacts the quality of life of the affected individuals. Peripheral nerve is known to regenerate itself when the defect is small. The mechanism of nerve repair and regeneration is complex and is related to neuroimmunomodulation where there is crosstalk between Schwann cells and macrophages which respond to the injury of smaller dimensions immediately. However, regeneration of large defects requires the use of grafts. 3D bioprinting is one such promising technology with which bioengineered nerve conduits can be reproduced for the repair of injured peripheral nerves. This review outlines the mechanism of repair and regeneration of peripheral nerves and provides a detailed description of the latest developments in the fabrication of bioengineered nerve conduits. Further, various bioprinting techniques and bioinks that have been established in vitro for the fabrication of nerve conduits are discussed. In addition, this article aims to look at the in vivo applications of the bioprinted nerve conduits with respect to different types of peripheral nerve models. The challenges and future perspectives involved in fabricating bioprinted functional nerve conduits have also been discussed.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400506","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Puerarin Ameliorates Premature Ovarian Failure by Activation of Mitochondrial Biogenesis, Dynamics, and Mitophagy Through Up-Regulation of SIRT1 葛根素通过上调SIRT1激活线粒体生物发生、动力学和线粒体自噬，改善卵巢早衰

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-26 DOI: 10.1002/adtp.202400310

Yuejuan Fang, Limei Huang, Fengyue Li, Xiuli Ding, Hongmei Zhou, Shun Xu

{"title":"Puerarin Ameliorates Premature Ovarian Failure by Activation of Mitochondrial Biogenesis, Dynamics, and Mitophagy Through Up-Regulation of SIRT1","authors":"Yuejuan Fang, Limei Huang, Fengyue Li, Xiuli Ding, Hongmei Zhou, Shun Xu","doi":"10.1002/adtp.202400310","DOIUrl":"https://doi.org/10.1002/adtp.202400310","url":null,"abstract":"Premature ovarian failure (POF) is characterized by ovarian atrophy and decreased fertility. Puerarin (Pue), an isoflavone compound, exerts protective effects on ovarian, however, with undefined mechanisms in POF. POF models were established by cyclophosphamide, and Pue and silent information regulator sirtuin 1 (SIRT1) inhibitor Selisistat (EX527) were used. Next, extracted primary rat ovarian granulosa cells (GCs) were treated with EX527 and autophagy activator rapamycin (RA). The data showed that in POF rats, Pue ameliorated estrous cycle, pathological damage, and senescence with higher ovarian index, anti-Müllerianhormone, estradiol, glutathione peroxidase, superoxide dismutase, mitochondrial DNA, and lower luteinizing hormone and follicle-stimulating hormone levels. In GCs, Pue increased cell viability, mitochondrial membrane potential, adenosine triphosphate levels, with decreased senescence and reactive oxygen species. Moreover, Pue induced mitophagy, enhanced peroxisome proliferators-activated receptor-γ coactivator-1alpha (PGC-1α), and reduced malondialdehyde, p16INK4a, p-adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK)/AMPK, mitochondrial transcription factor A, nuclear respiratory factor 1, dynamin-related protein 1, and mitochondrial fission 1 expression. Notably, the EX527 addition offset the above effects, while RA further reversed effects of EX527. In conclusion, Pue activated mitochondrial biogenesis, dynamics and mitophagy through up-regulation of SIRT1/PGC-1α pathway to ameliorate POF, providing a theoretical support for clinical application of Pue in POF.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"8 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Therapeutic Technologies for Malaria, Tuberculosis, HIV Infection and Neglected Tropical Diseases 疟疾、结核病、艾滋病毒感染和被忽视的热带病的先进治疗技术

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-23 DOI: 10.1002/adtp.202500115

Admire Dube, Garry Laverty, Mohammed Balogun

引用次数: 0

Issue Information (Adv. Therap. 3/2025) 发布信息（Adv. Therap. 3/2025）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2025-03-19 DOI: 10.1002/adtp.202570007

引用次数: 0